1.91
전일 마감가:
$1.76
열려 있는:
$1.78
하루 거래량:
9.88M
Relative Volume:
2.96
시가총액:
$314.98M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-95.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-18.72%
1개월 성능:
-20.42%
6개월 성능:
+139.86%
1년 성능:
+60.50%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
1.91 | 290.25M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-31 | 개시 | Oppenheimer | Outperform |
2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2025-04-14 | 재개 | Piper Sandler | Overweight |
2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
2021-11-15 | 개시 | BTIG Research | Buy |
2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2021-03-29 | 개시 | JP Morgan | Overweight |
2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
2020-05-14 | 재확인 | H.C. Wainwright | Buy |
2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
2020-03-04 | 개시 | Barclays | Equal Weight |
2019-11-20 | 개시 | Guggenheim | Buy |
2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-06-13 | 개시 | Mizuho | Buy |
2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
2019-03-11 | 개시 | Barclays | Overweight |
2018-11-26 | 개시 | Piper Jaffray | Overweight |
2018-10-15 | 개시 | Goldman | Neutral |
2018-09-13 | 개시 | H.C. Wainwright | Buy |
2018-06-01 | 개시 | SunTrust | Buy |
2018-01-05 | 개시 | Citigroup | Buy |
2017-09-08 | 개시 | Wedbush | Outperform |
2017-03-27 | 개시 | H.C. Wainwright | Buy |
2017-03-02 | 개시 | Instinet | Buy |
2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
What makes CytomX Therapeutics Inc. stock price move sharplyShare Buyback & High Return Trade Guides - sundaytimes.kr
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com Australia
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Announces Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M - Stock Titan
CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):